6-(溴甲基)-4-氯-2-(三氟甲基)喹啉 | 123637-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-(溴甲基)-4-氯-2-(三氟甲基)喹啉
• 英文名称: 6-(Bromomethyl)-4-chloro-2-(trifluoromethyl)quinoline
• 英文别名: 6-(bromomethyl)-4-chloro-2-trifluoromethylquinoline；6-bromomethyl-4-chloro-2-trifluoromethylquinoline
• CAS: 123637-51-4
• 化学式: C₁₁H₆BrClF₃N
• mdl: MFCD00153079
• 分子量: 324.528
• InChiKey: SJBKLFYWXYFAGT-UHFFFAOYSA-N

物化性质

• 熔点：
  119 °C
• 沸点：
  318.1±37.0 °C(Predicted)
• 密度：
  1.692±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi,C
• 安全说明：
  S26,S36,S36/37/39,S45
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090

SDS

Name:	6-(Bromomethyl)-4-chloro-2-(trifluoromethyl)quinoline 95+% Material Safety Data Sheet
Synonym:
CAS:	123637-51-4

Section 1 - Chemical Product MSDS Name:6-(Bromomethyl)-4-chloro-2-(trifluoromethyl)quinoline 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
123637-51-4	6-(Bromomethyl)-4-chloro-2-(trifluorom	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 123637-51-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 118 - 124 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H6BrClF3N
Molecular Weight: 325

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 123637-51-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-(Bromomethyl)-4-chloro-2-(trifluoromethyl)quinoline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 123637-51-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 123637-51-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 123637-51-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-(溴甲基)-4-氯-2-(三氟甲基)喹啉 在 吡啶 、 tin(II) chloride dihdyrate 、 sodium hydride 、 caesium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.75h， 生成 ethyl (E)-2-(5-((4-chloro-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-(4-fluorobenzamido)benzylidene)pentanoate
  参考文献：
  名称：

  新型PPARγ拮抗剂的结构优化。

  摘要：

  过氧化物酶体增殖物激活受体γ（PPARγ）调节剂已发现广泛用于治疗癌症，代谢紊乱和炎症性疾病。与PPARγ激动剂相反，对PPARγ拮抗剂的研究较少，尽管它们显示出免疫调节作用，但市场上仍没有治疗上有用的PPARγ拮抗剂。相反引起的2-氯-5-硝基苯甲酰苯胺（GW9662）非竞争性的，不可逆抑制，则最近描述（Ë）-2-（5-（（4-甲氧基-2-（三氟甲基）喹啉-6-基）甲氧基）-2-（（4-（三氟甲基）苄基氧基）-亚苄基）己酸（MTTB，T -10017）是新型PPARγ拮抗剂的有希望的原型。在HEK293T细胞的反式激活测定中，它对罗格列酮介导的PPARγ配体结合域（PPARγLBD）的活化具有竞争性拮抗作用，对1 µM罗格列酮的IC 50为4.3 µM。这项研究的目的是研究MTTB支架的结构-活性关系（SAR），重点是改善其理化特性。通过这种优化，制备并表征了34种新的衍生物。鉴定了两种

  DOI：

  10.1016/j.bmc.2019.115082
• 作为产物：
  描述：

  4-氯-6-甲基-2-(三氟甲基)喹啉 在 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 3.0h， 生成 6-(溴甲基)-4-氯-2-(三氟甲基)喹啉
  参考文献：
  名称：

  喹啉抗叶酸胸苷酸合酶抑制剂：C2-和C4-取代基的变异。

  摘要：

  强大的胸苷酸​​合酶（TS）抑制剂N- [4- [N-[（2-氨基-3,4-二氢-4-氧代-6-喹唑啉基）甲基] -N-prop-对双环系统的修饰2-炔基氨基]苯甲酰基] -L-谷氨酸（1，CB3717）已导致合成了一系列在C2和C4位带有多个取代基的喹啉抗叶酸酯。通常，合成途径包括将适当的N- [4-（丙-2-炔丙基氨基）苯甲酰基] -L-谷氨酸二乙酯与二取代的6-（溴甲基）喹啉偶联，然后使用弱碱将其脱保护。测试了该化合物作为部分纯化的L1210 TS的抑制剂。作为细胞毒性的量度，测试了化合物对培养物中L1210细胞生长的抑制作用。发现含有氯，氨基，在C2位的甲基取代基或在C4位的氯或溴取代基。改变2h N10取代基对酶的抑制作用与在含喹唑啉酮的叶酸中观察到的相似，表明喹啉化合物可能以与喹唑啉酮类似的方式与酶相互作用。同样，将2'-氟取代基引入几种喹啉类抗叶酸剂的苯甲酰基环中会导致TS抑

  DOI：

  10.1021/jm00093a007

文献信息

• Quinoline derivatives having anti-tumor activity
  申请人：Imperial Chemical Industries PLC

  公开号：US05112837A1

  公开（公告）日：1992-05-12

  The invention relates to a quinoline of the formula: ##STR1## wherein each of R.sup.1 and R.sup.2, which may be the same or different, is hydrogen, halogeno, hydroxy, cyano, carbamoyl, nitro or amino, alkyl, alkoxy, alkylthio, alkylamino, dialkylamino or alkanoylamino each of up to 4 carbon atoms, or substituted alkyl or alkoxy each of up to 3 carbon atoms, provided that both R.sup.1 and R.sup.2 are not hydrogen; the quinoline ring may bear further substituents; R.sup.3 is hydrogen or alkyl of up to 4 carbon atoms; R.sup.4 is hydrogen, alkyl, alkenyl or alkynyl each of up to 4 carbon atoms or substituted alkyl of up to 3 carbon atoms; Ar is phenylene, naphthylene or heterocyclene which is unsubstituted or which bears one or more substituents; R.sup.5 is such that R.sup.5 --NH.sub.2 is an amino acid; or a pharmaceutically-acceptable salt or ester thereof. The compounds possess anti-tumor activity.

  本发明涉及一种喹啉，其公式为：##STR1## 其中，R.sup.1和R.sup.2可以是相同的或不同的，为氢、卤素、羟基、氰基、碳酰胺基、硝基或氨基，为碳原子数不超过4的烷基、烷氧基、烷硫基、烷氨基、二烷氨基或烷酮氨基，或为碳原子数不超过3的取代烷基或取代烷氧基，但R.sup.1和R.sup.2均不为氢；喹啉环可带有进一步的取代基；R.sup.3为氢或碳原子数不超过4的烷基；R.sup.4为氢、碳原子数不超过4的烷基、烯基或炔基，或为碳原子数不超过3的取代烷基；Ar为二价苯基、二价萘基或杂环基，其中未取代或带有1个或多个取代基；R.sup.5满足R.sup.5 --NH.sub.2是一种氨基酸；或其药用可接受的盐或酯。这些化合物具有抗肿瘤活性。
• AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1844768A1

  公开（公告）日：2007-10-17

  The present invention provides a compound represented by the following formula (I): [wherein, A represents a group of the following formula (A-1): etc., R1 and R2 each independently represent a hydrogen atom etc., Z represents CR3 etc., W represents CR4 etc., Q represents CR5 etc., R3, R4 and R5 each independently represent a hydrogen atom etc., Y represents an oxygen atom or sulfur atom, X represents an oxygen atom etc. and B represents an optionally substituted aryl group or optionally substituted heteroaryl group], the prodrug thereof or the pharmaceutically acceptable salt thereof for preventing or treating various diseases such as hypertesion, cerebral stroke, cardiac failure, etc.

  本发明提供了以下式（I）所表示的化合物： [其中，A表示以下式（A-1）的基团： 等等，R1和R2分别独立表示氢原子等，Z表示CR3等，W表示CR4等，Q表示CR5等，R3、R4和R5分别独立表示氢原子等，Y表示氧原子或硫原子，X表示氧原子等，B表示可选择地取代的芳基或可选择地取代的杂环基]，其前药或其药学上可接受的盐，用于预防或治疗高血压、脑卒中、心力衰竭等各种疾病。
• Carbonylative Coupling of Alkyl Zinc Reagents with Benzyl Bromides Catalyzed by a Nickel/NN ₂  Pincer Ligand Complex
  作者：Thomas L. Andersen、Aske S. Donslund、Karoline T. Neumann、Troels Skrydstrup

  DOI：10.1002/anie.201710089

  日期：2018.1.15

  An efficient catalytic protocol for the three‐component assembly of benzyl bromides, carbon monoxide, and alkyl zinc reagents to give benzyl alkyl ketones is described, and represents the first nickel‐catalyzed carbonylative coupling of two sp3‐carbon fragments. The method, which relies on the application of nickel complexed with an NN2‐type pincer ligand and a controlled release of CO gas from a solid

  描述了一种高效的催化方案，用于三组分组装苄基溴，一氧化碳和烷基锌试剂，得到苄基烷基酮，它代表了两个sp 3-碳片段的第一个镍催化的羰基化偶联。该方法依赖于将镍与NN 2型钳形配位体配合使用，以及从固体前体中控制释放CO气体的方法，适用于一系列苄基溴化物。机理研究表明，以碳为中心的自由基是中间的。
• ORGANIC COMPOUNDS
  申请人：Dales Natalie

  公开号：US20090156615A1

  公开（公告）日：2009-06-18

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了调节硬脂酰辅酶A去饱和酶活性的杂环衍生物。还涵盖了利用这些衍生物调节硬脂酰辅酶A去饱和酶活性的方法以及包含这些衍生物的药物组合物。
• Parallel solution-phase syntheses of functionalised bicyclo[2.2.2]octanes: generation of a library using orchestrated multi-step sequences of polymer-supported reagents and sequesterants
  作者：Steven V. Ley、Alessandro Massi

  DOI：10.1039/b003129l

  日期：——

  An array of bicyclo[2.2.2]octane derivatives was prepared in high yield using an orchestrated multi-step sequence of polymer-supported reagents and sequestering agents, without any chromatographic purification steps. Nine intermediate libraries were synthesised, with the final library possessing five sites of diversity. Key steps included an efficient tandem Michael addition reaction of acrylates with cyclohexenones and a subsequent reductive amination reaction.

  利用聚合物支撑试剂和螯合剂的协调多步骤序列，制备了一系列双环[2.2.2]辛烷衍生物，产量很高，且无需任何色谱纯化步骤。合成了九个中间文库，最终文库具有五个多样性位点。关键步骤包括丙烯酸酯与环己烯酮的高效串联迈克尔加成反应以及随后的还原胺化反应。